LIFE SAVING DRUGS PROGRAM EXPERT PANEL

NINTH MEETING: 17 June 2021

# AGENDA

## Standing business

* 1. Welcome & apologies
  2. Declaration of potential or actual Conflict of Interest
  3. Correspondence
  4. Report from the Secretariat

## 24-month Reviews

* 1. Cerliponase (Brineura®) for the treatment of Late-Infantile Onset Batten disease (CLN2)
  2. Migalastat (Galafold®) for the treatment of Fabry disease

## Managed Access Program

* 1. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IV-A (MPS IVA)

## Other business